Mouse Monoclonal Zyxin antibody. Suitable for WB and reacts with Human samples. Cited in 9 publications. Immunogen corresponding to Synthetic Peptide within Human ZYX aa 100-150 conjugated to Keyhole Limpet Haemocyanin.
View Alternative Names
Zyxin, Zyxin-2, ZYX
- WB
Lab
Western blot - Anti-Zyxin antibody [ZOL301] (AB50391)
Lanes 1 - 4 : Merged signal (red and green). Green - ab50391 observed at 75 kDa. Red - loading control ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) observed at 37 kDa.
ab50391 was shown to react with ZYX in wild-type HEK-293T cells in Western blot with loss of signal observed in ZYX knockout cell line ab266504 (ZYX knockout cell lysate ab257810). Wild-type HEK-293T and ZYX knockout cell lysates were subjected to SDS-PAGE. Membranes were blocked in 3 % milk in TBS-T (0.1 % Tween®) before incubation with ab50391 and ab181602 (Rabbit Anti-GAPDH antibody [EPR16891]) overnight at 4 °C at a 1 in 1000 dilution and a 1 in 20000 dilution respectively. Blots were incubated with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) secondary antibodies at 1 in 20000 dilution for 1 h at room temperature before imaging.
All lanes:
Western blot - Anti-Zyxin antibody [ZOL301] (ab50391) at 1/1000 dilution
Lane 1:
Wild-type HEK-293T cell lysate at 20 µg
Lane 2:
ZYX knockout HEK-293T cell lysate at 20 µg
Lane 2:
Western blot - Human ZYX (Zyxin) knockout HEK-293T cell line (<a href='/en-us/products/cell-lines/human-zyx-zyxin-knockout-hek-293t-cell-line-ab266504'>ab266504</a>)
Lane 3:
HeLa cell lysate at 20 µg
Lane 4:
Daudi cell lysate at 20 µg
Predicted band size: 61 kDa
Observed band size: 75 kDa
false
- WB
Lab
Western blot - Anti-Zyxin antibody [ZOL301] (AB50391)
False colour image of Western blot : Anti-Zyxin antibody [ZOL301] staining at 1/1000 dilution, shown in green; Rabbit Anti-GAPDH antibody [EPR16891] (ab181602) loading control staining at 1/20000 dilution, shown in red. In Western blot, ab50391 was shown to bind specifically to Zyxin. A band was observed at 75 kDa in wild-type HEK-293T cell lysates with no signal observed at this size in ZYX CRISPR-Cas9 edited cell line ab266503 (CRISPR-Cas9 edited cell lysate ab257809). The band observed in the CRISPR-Cas9 edited lysate lane below 75 kDa is likely to represent a truncated form of Zyxin. This has not been investigated further and the functional properties of the gene product have not been determined. To generate this image, wild-type and ZYX CRISPR-Cas9 edited HEK-293T cell lysates were analysed. First, samples were run on an SDS-PAGE gel then transferred onto a nitrocellulose membrane. Membranes were blocked in 3 % milk in TBS-0.1 % Tween® 20 (TBS-T) before incubation with primary antibodies overnight at 4 °C. Blots were washed four times in TBS-T, incubated with secondary antibodies for 1 h at room temperature, washed again four times then imaged. Secondary antibodies used were Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (ab216777) at 1/20000 dilution.
All lanes:
Western blot - Anti-Zyxin antibody [ZOL301] (ab50391) at 1/1000 dilution
Lane 1:
Wild-type HEK-293T cell lysate at 20 µg
Lane 2:
ZYX CRISPR-Cas9 edited HEK-293T cell lysate at 20 µg
Lane 3:
HeLa cell lysate at 20 µg
Lane 4:
Daudi cell lysate at 20 µg
Predicted band size: 61 kDa
Observed band size: 75 kDa
false
Reactivity data
Product details
Properties and storage information
Form
Purity
Purification notes
Storage buffer
Shipped at conditions
Appropriate short-term storage duration
Appropriate short-term storage conditions
Appropriate long-term storage conditions
Aliquoting information
Storage information
Supplementary information
This supplementary information is collated from multiple sources and compiled automatically.
Biological function summary
The protein has important roles in cellular processes such as migration and morphology. Zyxin often forms part of a larger protein complex that includes VASP and α-actinin which contribute to cell scaffolding and structural integrity. It serves as an organizer for cytoskeletal proteins ensuring proper cell movement and adaptability to cellular stress. Its actin-binding capacity enables it to regulate structural changes necessary for cellular adaptation to environmental stimuli.
Pathways
This protein is essential in the regulation of actin cytoskeleton associated pathways and adherens junction signaling. Zyxin interacts with Ena/VASP proteins which are significant in actin filament elongation helping regulate dynamic changes in cell shape and motility. Its relationship with LIM domain-containing proteins positions zyxin within pathways related to cell proliferation and signal transduction.
Product protocols
- Visit the General protocols
- Visit the Troubleshooting
Target data
Publications (9)
Recent publications for all applications. Explore the full list and refine your search
Reports of biochemistry & molecular biology 11:262-269 PubMed36164635
2022
Applications
Unspecified application
Species
Unspecified reactive species
iScience 25:104123 PubMed35402867
2022
Applications
Unspecified application
Species
Unspecified reactive species
The Journal of cell biology 220: PubMed33999101
2021
Applications
Unspecified application
Species
Unspecified reactive species
Turkish journal of biology = Turk biyoloji dergisi 44:381-392 PubMed33402865
2020
Applications
Unspecified application
Species
Unspecified reactive species
Journal of experimental & clinical cancer research 37:221 PubMed30200999
2018
Applications
Unspecified application
Species
Unspecified reactive species
Nature communications 8:14639 PubMed28256511
2017
Applications
Unspecified application
Species
Unspecified reactive species
Biomaterials 33:4998-5003 PubMed22516607
2012
Applications
WB, ICC/IF
Species
Human, Human
PloS one 7:e31423 PubMed22348083
2012
Applications
ICC/IF
Species
Human
ASN neuro 1: PubMed19743964
2009
Applications
ICC/IF, WB
Species
Rat, Rat
Product promise
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com